Drugs / N-acetyl-D-glucosamine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01893606 | Apr 2013 → Dec 2016 | irritable bowel syndrome | Third Military Medical University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02504060 | Jun 2015 → Dec 2016 | irritable bowel syndrome | Third Military Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetyl-D-glucosamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01893606 ↗ |
| Modality | Small molecule | “1.1 chemical drugs N-acetyl-D-glucosamine” NCT02504060 ↗ |
| Route | Oral | “During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.” NCT01893606 ↗ |